Video

Alasdair Coles, MD

CARE MS extension study results, discussed by Dr. Alasdair Coles at the 2014 Joint ACTRIMS-ECTRIMS meeting in Boston, provide further evidence of the prolonged efficacy of alemtuzumab on both relapses and disability in multiple sclerosis.


 

References

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

Cannabis May Not Be a Panacea
ICYMI Multiple Sclerosis
Alfacalcidol May Reduce MS-Related Fatigue
ICYMI Multiple Sclerosis
How Do Vaccinations Affect Patients With MS?
ICYMI Multiple Sclerosis
Robert Fox, MD
ICYMI Multiple Sclerosis
Targeting B Cells May Help With MS
ICYMI Multiple Sclerosis
How Common Is Medical Marijuana Use Among Patients With MS?
ICYMI Multiple Sclerosis
Clinical and Subclinical Factors Strongly Influence MS Treatment Decisions
ICYMI Multiple Sclerosis
Alemtuzumab’s Benefits May Be Sustained for Three Years in Patients With MS
ICYMI Multiple Sclerosis
Can Lesion Volume and Brain Atrophy Predict Outcomes in Early MS?
ICYMI Multiple Sclerosis
Automating and Improving the EDSS—Validation of the eEDSS
ICYMI Multiple Sclerosis